Nautilus Biotechnology Forecast, price target & analysts
Nautilus Biotechnology Target price 2026 - Analyst rating & recommendation
Nautilus Biotechnology Classifications & Recommendation
Nautilus Biotechnology Price Target
| Target Price | $4.08 |
| Price | $0.96 |
| Potential |
323.81%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Nautilus Biotechnology 2027 .
The average Nautilus Biotechnology target price is $4.08.
This is
323.81%
register free of charge
$4.20
336.27%
register free of charge
$4.04
319.65%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend Nautilus Biotechnology to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Nautilus Biotechnology stock has an average upside potential 2027 of
323.81%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 0.56 |
5 Analysts have issued a sales forecast Nautilus Biotechnology 2026 . The average Nautilus Biotechnology sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Nautilus Biotechnology EBITDA forecast 2026. The average Nautilus Biotechnology EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Nautilus Biotechnology Analysts have issued a net profit forecast 2026. The average Nautilus Biotechnology net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.47 | -0.52 |
| 16.07% | 10.64% | |
| P/E | negative | |
| EV/Sales | 68.80 |
4 Analysts have issued a Nautilus Biotechnology forecast for earnings per share. The average Nautilus Biotechnology EPS is
This results in the following potential growth metrics and future valuations:
Nautilus Biotechnology...
Current Nautilus Biotechnology Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Leerink Partners |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Feb 27 2026 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Dec 05 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Feb 27 2026 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Dec 05 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
